The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Primary Myelofibrosis

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about Primary Myelofibrosis.
Olatoyosi Odenike
Connection Strength
2.842
Primary Myelofibrosis
  1. Novel Therapies for Myelofibrosis. Curr Hematol Malig Rep. 2017 12; 12(6):611-624.
    View in: PubMed
    Score: 0.588
  2. Beyond JAK inhibitor therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2013; 2013:545-52.
    View in: PubMed
    Score: 0.418
  3. Myelofibrosis with myeloid metaplasia: where is the biology leading us? Semin Oncol. 2005 Aug; 32(4):357-8.
    View in: PubMed
    Score: 0.250
  4. Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):422-31.
    View in: PubMed
    Score: 0.250
  5. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 Oct 24; 144(17):1813-1820.
    View in: PubMed
    Score: 0.237
  6. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11(5):e383-e389.
    View in: PubMed
    Score: 0.228
  7. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 09 10; 39(26):2881-2892.
    View in: PubMed
    Score: 0.188
  8. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
    View in: PubMed
    Score: 0.134
  9. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015 May; 50(5):628-36.
    View in: PubMed
    Score: 0.121
  10. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014 Dec; 9(4):350-9.
    View in: PubMed
    Score: 0.119
  11. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81.
    View in: PubMed
    Score: 0.111
  12. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31(6):737-40.
    View in: PubMed
    Score: 0.069
  13. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503.
    View in: PubMed
    Score: 0.066
  14. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137.
    View in: PubMed
    Score: 0.034
  15. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.